Develops therapies for inflammatory and autoimmune diseases using its proprietary platform.
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for renal and inflammatory diseases. The company's primary focus includes VAR 200, a cholesterol efflux mediator designed to treat conditions such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. This therapeutic approach aims to address significant unmet medical needs in the field of nephrology.
In addition to its renal disease portfolio, ZyVersa Therapeutics is advancing IC 100, a novel inflammasome ASC inhibitor targeting a range of inflammatory diseases. This groundbreaking treatment aims to modulate the body's inflammatory response, offering potential relief for patients suffering from various chronic inflammatory conditions.
Headquartered in Weston, Florida, ZyVersa Therapeutics is at the forefront of biopharmaceutical innovation, leveraging cutting-edge science to develop therapies that improve patient outcomes and quality of life. The company's commitment to addressing both renal and inflammatory diseases underscores its dedication to advancing healthcare and providing new solutions for challenging medical conditions.